Latest Information Update: 17 Dec 2003
At a glance
- Originator Unknown
- Developer Johnson & Johnson Pharmaceutical Research & Development LLC; Nonindustrial source; Nonindustrial sources
- Class Antineoplastics
- Mechanism of Action Mitogen-activated protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Stroke